ClinicalTrials.gg
Active, not recruitingNCT06369298RENEU-HFUpdated May 22, 2026

Study of JK07 in Patients With Chronic Heart Failure

A Phase 2 interventional study of JK07 and Placebo in Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction, sponsored by Salubris Biotherapeutics Inc. Active, not recruiting at 62 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Salubris Biotherapeutics Inc (part of Shenzhen Salubris Pharmaceuticals Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
385th of 1,601
282 · median 65
Started
2024
with 107 others
Phase 2
227 of 2,157
26 open now
Primary completion
2026-10
later than 111 of 436 live
Registered
1,910th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 385th largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2024, is one of 227 in phase 2, reaches primary completion later than 111 of the 436 other live ones, and was the 1,910th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.

There will be 2 cohorts in this study:

Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%.

Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) > 40% and ≤ 65%.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Preserved Ejection Fraction

Keywords

  • Heart Failure
  • Heart Failure with Reduced Ejection Fraction
  • Heart Failure with Preserved Ejection Fraction
  • Heart Failure NYHA Class III
  • Heart Failure NYHA Class II
  • Heart Failure with Atrial Fibrillation/Flutter
  • HFrEF
  • HFpEF
  • Neuregulin 1
  • NRG-1
  • HER3
  • HER4
  • ErbB3
  • ErbB4
  • Systolic Heart Failure
  • Diastolic Heart Failure
  • Atrial Fibrillation
  • Atrial Flutter
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with (NYHA) Class II-III.
  • Cohort 1 - (LVEF) ≤ 40%.
  • Cohort 2 - Left Ventricular Ejection Fraction (LVEF) >40% and ≤ 65%, elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥ 600pg/mL and atrial fibrillation/flutter.
  • Stable heart failure and on optimal medical therapy.
  • Screening ≥ 9.0 g/dL.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension.
  • Sustained systolic Blood Pressure (BP) \< 90 mmHg and/or diastolic BP \< 50 mmHg on 2 consecutive (duplicate seated) readings at screening.
  • Heart failure due to hypertrophic cardiomyopathy, restrictive and/or infiltrative cardiomyopathy, arrhythmogenic right ventricular dysplasia, Fabry disease, or Noonan syndrome with LV hypertrophy or a positive serum immunofixation result.
  • Diagnosis of stress-induced (Takotsubo) cardiomyopathy, myocarditis, or peripartum cardiomyopathy.
  • Diagnosis of chemotherapy- or radiation-induced cardiomyopathy.
  • Diagnosed with stroke or (TIA) within 12 weeks of screening.
  • History of syncope within the last 12 weeks prior to screening or sustained ventricular tachycardia without an implantable cardioverter-defibrillator.
  • Moderate or severe aortic and/or mitral valve stenosis.
  • Medically documented unstable angina, acute coronary syndrome (e.g., myocardial infarction, troponin-positive with symptoms of angina or unstable angina) within the last 8 weeks prior to start of screening.
  • Medically documented ST-elevation myocardial infarction within 12 weeks of screening.
  • Any tachycardia (inclusive of Atrial Fibrillation (AF) or atrial flutter) with a resting ventricular rate > 110 beats per minute at screening.
  • For participants with a history of AF or atrial flutter, not on adequate anticoagulant therapy via non-vitamin K oral anticoagulants or warfarin if the CHA2DS2-VASc score is ≥ 2 in men or ≥ 3 in women or per local guidelines. Percutaneous occlusion of the left atrial appendage alone is not adequate.
  • AF ablation within the last 12 weeks prior to screening or planned during the study duration.
  • Symptomatic bradycardia or second (Mobitz Type II)- or third-degree heart block without a pacemaker.
  • Cardiac surgery, coronary artery revascularization or indication for coronary artery revascularization, percutaneous coronary intervention, valve repair/replacement or valvuloplasty within 12 weeks prior to screening.
  • Implantation of a Cardiac Resynchronization Therapy (CRT) device within 12 weeks prior to screening, or intent to implant a CRT device during the course of the study.
  • Previous cardiac transplantation, or any use of mechanical circulatory support or similar device, or implantation expected after randomization.
  • Receiving mechanical hemodynamic support or invasive mechanical ventilation within the last 8 weeks prior to screening.
  • Receiving Intravenous (IV) inotropes or IV vasopressors within the last 8 weeks prior to screening.
  • Receiving IV vasodilators within the last 4 weeks prior to screening.
  • Receiving noninvasive mechanical ventilation within the last 4 weeks prior to screening. The use of noninvasive ventilation for sleep disordered breathing is permitted.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
282 participants (estimated)

Study arms

  • Active comparator
    JK07 low dose

    JK07 administered by intravenous (IV) infusion

    Drug: JK07

  • Active comparator
    JK07 high dose

    JK07 administered by intravenous (IV) infusion

    Drug: JK07

  • Placebo comparator
    Placebo

    Placebo administered by intravenous (IV) infusion

    Drug: Placebo

Interventions

  • DrugJK07

    JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.

  • DrugPlacebo

    0.9% sodium chloride

06

What researchers measure

Primary outcomes

  1. Safety - Cohort 1

    Incidence and severity of treatment emergent adverse events

    Time frame: Study entry through week 52

  2. Efficacy - Cohort 1

    Change in LVEF measured by 2D-TTE

    Time frame: Baseline through week 26

  3. Safety - Cohort 2

    Incidence and severity of treatment emergent adverse events

    Time frame: Study entry through week 52

07

Study locations

62 sites
  • Site 121
    Alexander City, Alabama 35010, United States
  • Site 130
    Birmingham, Alabama 35211, United States
  • Site 139
    Birmingham, Alabama 35294, United States
  • Site 138
    Huntsville, Alabama 35801, United States
  • Site 111
    Phoenix, Arizona 85016, United States
  • Site 127
    Little Rock, Arkansas 72205, United States
  • Site 128
    Huntington Beach, California 92648, United States
  • Site 157
    Los Angeles, California 90033, United States
  • Site 158
    Orange, California 92868, United States
  • Site 116
    Pasadena, California 91105, United States
  • Site 129
    Santa Maria, California 93454, United States
  • Site 102
    Stanford, California 94305, United States
  • Site 113
    Torrance, California 90502, United States
  • Site 133
    Vista, California 92081, United States
  • Site 161
    Coral Gables, Florida 33134, United States
  • Site 114
    Hialeah, Florida 33016, United States
  • Site 162
    Miami Lakes, Florida 33014, United States
  • Site 159
    Naples, Florida 34104, United States
  • Site 136
    Atlanta, Georgia 30343, United States
  • Site 143
    Boise, Idaho 83712, United States
  • Site 160
    Chicago, Illinois 60611, United States
  • Site 154
    Park Ridge, Illinois 60068, United States
  • Site 137
    Fort Wayne, Indiana 46804, United States
  • Site 112
    Indianapolis, Indiana 46250, United States
  • Site 104
    Covington, Louisiana 70433, United States
  • Site 118
    Baltimore, Maryland 21201, United States
  • Site 119
    Boston, Massachusetts 02114, United States
  • Site 122
    Bloomfield Hills, Michigan 48304, United States
  • Site 150
    Farmington Hills, Michigan 48334, United States
  • Site 107
    Rochester, Minnesota 55905, United States
  • Site 106
    St Louis, Missouri 63110, United States
  • Site 105
    St Louis, Missouri 63136, United States
  • Site 144
    Brick, New Jersey 08724, United States
  • Site 153
    Valhalla, New York 10595, United States
  • Site 152
    Asheville, North Carolina 28803, United States
  • Site 109
    Cary, North Carolina 27518, United States
  • Site 140
    Charlotte, North Carolina 28204, United States
  • Site 145
    Durham, North Carolina 27710, United States
  • Site 117
    Cincinnati, Ohio 45219, United States
  • Site 100
    Cleveland, Ohio 44195, United States
  • Site 135
    Oklahoma City, Oklahoma 73135, United States
  • Site 101
    Portland, Oregon 97239, United States
  • Site 155
    York, Pennsylvania 17403, United States
  • Site 110
    Dallas, Texas 75235, United States
  • Site 115
    Dallas, Texas 75246, United States
  • Site 103
    Houston, Texas 77030, United States
  • Site 149
    Tomball, Texas 77375, United States
  • Site 148
    Arlington, Virginia 22205, United States
  • Site 123
    Falls Church, Virginia 22042, United States
  • Site 126
    Norfolk, Virginia 23507, United States
  • Site 163
    Vienna, Virginia 22182, United States
  • Site 202
    Winnepeg, Manitoba R2H2A6, Canada
  • Site 203
    Brampton, Ontario L6Z 4N5, Canada
  • Site 200
    Chicoutimi, Quebec G7H 7K9, Canada
  • Site 201
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Site 305
    Changsha, Hunan 410005, China
  • Site 303
    Nanjing, Jiangsu 210009, China
  • Site 306
    Jining, Shandong 272100, China
  • Site 301
    Chengdu, Sichuan 610041, China
  • Site 300
    Beijing, 100037, China
  • Site 304
    Chongqing, 404000, China
  • Site 156
    Ponce, 00717, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2026, 31 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 31 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 16, 2024
StartActual
Mar 28, 2024
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06369298
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Mar 28, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
May 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JK07

Start the discussion